Zobrazeno 1 - 10
of 74
pro vyhledávání: '"Sara Baglivo"'
Autor:
Giulio Metro, Eleonora Gariazzo, Silvia Costabile, Sara Baglivo, Fausto Roila, Francesca Colamartini, Barbara Palumbo, Pietro Chiarini, Stefania Gori, Antonio Conti, Luca Marcomigni, Guido Bellezza, Gianluigi Lunardi
Publikováno v:
Oncology and Therapy, Vol 12, Iss 1, Pp 163-171 (2023)
Abstract In this work, we report on a clinically significant response of meningeal carcinomatosis to repotrectinib in a woman with a heavily pretreated ROS1-rearranged non-small cell lung cancer (NSCLC) that harbored the concomitant solvent front G20
Externí odkaz:
https://doaj.org/article/3a4ed1b09b5d4c588436e9abe5843e1f
Autor:
Giulio Metro, Eleonora Gariazzo, Silvia Costabile, Sara Baglivo, Fausto Roila, Francesca Colamartini, Barbara Palumbo, Pietro Chiarini, Stefania Gori, Antonio Conti, Luca Marcomigni, Guido Bellezza, Gianluigi Lunardi
Publikováno v:
Oncology and Therapy, Vol 12, Iss 1, Pp 173-174 (2024)
Externí odkaz:
https://doaj.org/article/721958e30de148fbbf729425efe8aa14
Autor:
Matteo Canale, Elisabetta Petracci, Paola Cravero, Marita Mariotti, Gabriele Minuti, Giulio Metro, Vienna Ludovini, Sara Baglivo, Maurizio Puccetti, Alessandra Dubini, Giovanni Martinelli, Angelo Delmonte, Lucio Crinò, Paola Ulivi
Publikováno v:
Translational Oncology, Vol 23, Iss , Pp 101471- (2022)
Non-small-cell lung cancer (NSCLC) is the primary cause of cancer-related death. Gene rearrangements involving the anaplastic lymphoma kinase (ALK) tyrosine kinase identify a clinical and molecular subset of NSCLC patients, who benefit from the monot
Externí odkaz:
https://doaj.org/article/9fcffe32bbf24565b0725968e3ffe4ea
Publikováno v:
Oncology and Therapy, Vol 8, Iss 2, Pp 341-350 (2020)
Abstract Oncogene-addicted non-small cell lung cancer (NSCLC) comprises a number of distinct disease subtypes, each of which is characterised by druggable genetic alterations. Among them, the receptor tyrosine kinase protein human epidermal receptor
Externí odkaz:
https://doaj.org/article/95a6b73ec2c3469890dcc2c163bee1e2
Autor:
Sara Baglivo, Vienna Ludovini, Riccardo Moretti, Guido Bellezza, Angelo Sidoni, Fausto Roila, Giulio Metro
Publikováno v:
Oncology and Therapy, Vol 8, Iss 2, Pp 333-339 (2020)
Abstract Patients with epidermal growth factor receptor and anaplastic lymphoma kinase positive non-small cell lung cancer (NSCLC) generally respond poorly to treatment with immune checkpoint inhibitors such as anti-programmed cell death-1 (PD-1) or
Externí odkaz:
https://doaj.org/article/f2f94527ae4c4133915f96ff3e4827bb
Autor:
Elisa Baldelli, Emna El Gazzah, John Conor Moran, Kimberley A. Hodge, Zarko Manojlovic, Rania Bassiouni, John D. Carpten, Vienna Ludovini, Sara Baglivo, Lucio Crinò, Fortunato Bianconi, Ting Dong, Jeremy Loffredo, Emanuel F. Petricoin, Mariaelena Pierobon
Publikováno v:
Genes, Vol 12, Iss 9, p 1402 (2021)
KRAS mutations are one of the most common oncogenic drivers in non-small cell lung cancer (NSCLC) and in lung adenocarcinomas in particular. Development of therapeutics targeting KRAS has been incredibly challenging, prompting indirect inhibition of
Externí odkaz:
https://doaj.org/article/f9eecad718b64cdf953c0e9b96836030
Autor:
Sara Baglivo, Fortunato Bianconi, Giulio Metro, Alessio Gili, Francesca Romana Tofanetti, Guido Bellezza, Biagio Ricciuti, Martina Mandarano, Valeria Teti, Annamaria Siggillino, Maria Sole Reda, Rita Chiari, Lorenza Pistola, Angelo Sidoni, Vincenzo Minotti, Fausto Roila, Vienna Ludovini
Publikováno v:
Genes, Vol 12, Iss 7, p 992 (2021)
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of lung cancer. However, their clinical benefit is limited to a minority of patients. To unravel immune-related factors that are predictive of sensitivity or resistance to immunoth
Externí odkaz:
https://doaj.org/article/9616edf7ce244c6bae96a87a6b11bd3e
Autor:
Martina Mandarano, Elena Orecchini, Guido Bellezza, Jacopo Vannucci, Vienna Ludovini, Sara Baglivo, Francesca Romana Tofanetti, Rita Chiari, Elisabetta Loreti, Francesco Puma, Angelo Sidoni, Maria Laura Belladonna
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 9, p 4403 (2021)
The enzyme indoleamine 2,3-dioxygenase 1 (IDO1) degrade tryptophan (Trp) into kynurenine (Kyn) at the initial step of an enzymatic pathway affecting T cell proliferation. IDO1 is highly expressed in various cancer types and associated with poor progn
Externí odkaz:
https://doaj.org/article/ad25d721f4b0427089cf47b40c777dee
Autor:
Giulio Metro, Sara Baglivo, Guido Bellezza, Martina Mandarano, Alessio Gili, Giovanni Marchetti, Marco Toraldo, Carmen Molica, Maria Sole Reda, Francesca Romana Tofanetti, Annamaria Siggillino, Enrico Prosperi, Antonella Giglietti, Bruna Di Girolamo, Miriam Garaffa, Francesca Marasciulo, Vincenzo Minotti, Marco Gunnellini, Annalisa Guida, Monica Sassi, Angelo Sidoni, Fausto Roila, Vienna Ludovini
Publikováno v:
Genes, Vol 12, Iss 5, p 679 (2021)
Besides platinum-based chemotherapy, no established treatment option exists for advanced non-small-cell lung cancer (NSCLC) patients with EGFR exon 20 (Ex20ins) insertion mutations. We sought to determine the clinical outcome of patients with this EG
Externí odkaz:
https://doaj.org/article/70b79d0f7ed14f21accc9fc53fac23d1
Autor:
Elisa Baldelli, Mahalakshmi Subramanian, Abduljalil M. Alsubaie, Guy Oldaker, Maria Emelianenko, Emna El Gazzah, Sara Baglivo, Kimberley A. Hodge, Fortunato Bianconi, Vienna Ludovini, Lucio Crino’, Emanuel F. Petricoin, Mariaelena Pierobon
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 6, p 2819 (2021)
Targetable alterations in cancer offer novel opportunities to the drug discovery process. However, pre-clinical testing often requires solubilization of these drugs in cosolvents like dimethyl sulfoxide (DMSO). Using a panel of cell lines commonly us
Externí odkaz:
https://doaj.org/article/4662241e81ab4ae4b6c2aac8cda44a2d